Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Dev Dyn. 2018 Apr 10;247(6):818–831. doi: 10.1002/dvdy.24627

Figure 4. Shh and GliA activity are required in NCCs for SMG development.

Figure 4

(A, D, G, J, M, P) H&E staining on frontal sections of wild-type, Kif3af/f;Wnt1-Cre, Smof/f;Wnt1-Cre, Gli2f/f;Gli3f/f;Wnt1-Cre, Gli2f/f;Gli3d699;Wnt1-Cre, and ROSAGli3TFlag;Wnt1-Cre embryos. Dotted black lines indicate developing and mutant SMGs. (A’, D’, G’, J’, M’, P’) High-magnification images of A, D, G, J, M, P. (B, E, H, K, N, Q) Anti-Pdgfrβ immunostaining (green) on wild-type, Kif3af/f;Wnt1-Cre, Smof/f;Wnt1-Cre, Gli2f/f;Gli3f/f;Wnt1-Cre, Gli2f/f;Gli3d699;Wnt1-Cre, and ROSAGli3TFlag;Wnt1-Cre SMGs or mutant mesenchymal capsules (dotted white lines). (C, F, I, L, O, R) Anti-Krt8 immunostaining (red) on wild-type, Kif3af/f;Wnt1-Cre, Smof/f;Wnt1-Cre, Gli2f/f;Gli3f/f;Wnt1-Cre, Gli2f/f;Gli3d699;Wnt1-Cre, and ROSAGli3TFlag;Wnt1-Cre SMGs or mutant mesenchymal capsules (dotted white lines). Nuclei counterstained with Hoechst. Scale bars= (A, D, G, J, M, P) 1mm; (A’, B, C, D’, E, F, G’, H, I, J’, K, L, M’, N, O, P’, Q, R) 100μm.